Latest news and research on all cancers and treatments, updated several times a week, plus 10,000-item data base of these
Immunotherapy is a new class of treatment that is changing the way many doctors and researchers think aboutcancer. The goal of immunotherapy is ...
A novel combination therapy achieved near complete remission in mouse models of advanced prostate cancer. In the image, micrograph of prostate ...
Crowned Science magazine's 'Breakthrough of the Year' in 2013, cancer immunotherapy has shown no sign of slowing down in terms of the level of ...
The PD-1 inhibitor pembrolizumab, a cancer immunotherapy drug, shrank or halted growth of tumors in 76% of patients with pleural mesothelioma.
| Drug Discovery & Development |
Among vaccines under study in prostate cancer, PROSTVAC is a ... a prostate-specific antigen-targeting cancer immunotherapy [press release].
... for Cancer Research (AACR) Annual Meeting 2015 in Philadelphia, Pennsylvania. "We've had wonderful success with immunotherapies, but we are ...
In a new study entitled “Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity” published in Nature, a newly-designed ...
The field of prostate cancer vaccines remains an area of active exploration, ... Live attenuated Listeria-based vaccines can generate immune system ...
Cardiff University scientists have developed a novel anti-cancer stem cell agent ... including cancer stem cells from human breast cancer patient biopsies. ... mechanism against the immune system and second to prevent its regrowth.
What if there was a vaccine proven to prevent a type of cancer? ... "When you're younger in age your immune system has a better response to the ...
Most cancer patients must wait five years after removal of a tumor to be ... That's because doctors fear microscopic leftover cells or new cancer cells could ... tumor cells have this unique capability to hijack the immune system to do its ...
Paucity of Somatic Mutations in Aggressive Childhood Leukemia
Results from a study in the March 2015 issue of Nature Genetics show that a particularly aggressive form of infant and childhood leukemia is likely driven by a chromosomal translocation.
Results from a study in the March 2015 issue of Nature Genetics show that a particularly aggressive form of infant and childhood leukemia is likely driven by a chromosomal translocation.
Interferon Could Help CML Patients Stop TKI Therapy
A small study suggests that induction treatment with interferon alpha 2a (IFN) along with imatinib, followed by temporary IFN maintenance therapy, could help chronic myeloid leukemia patients discontinue imatinib treatment.
A small study suggests that induction treatment with interferon alpha 2a (IFN) along with imatinib, followed by temporary IFN maintenance therapy, could help chronic myeloid leukemia patients discontinue imatinib treatment.
Fusion Protein Shows Potency Against Leukemia Cells
A new "fusion protein" can possibly open a new range of effective treatment opportunities for children with recurrent leukemia.
A new "fusion protein" can possibly open a new range of effective treatment opportunities for children with recurrent leukemia.
According to researchers, invasive bladder cancer affects more than 375,000 people across the world each year. The cancer is largely untreatable ...
BACKGROUND: Epidemiological studies have reported inconsistent association between obesity and risk ofbladder cancer, and the dose-response ...
The objective of this systematic review was to assess the overall diagnostic accuracy of 18 F FDG-PET and PET/CT in urinary bladder cancer with ...
BERKELEY, CA (UroToday.com) - Bladder cancer is the second most common malignancy of the urinary tract and the fourth most frequent cancer in ...
Oncologists in the not too distant future may have a urine test to screen for bladder cancer. Colorado investigators reported at the American ...
UroToday
Conventionally used clinicopathological factors are associated with certain limitations regarding the accurate prediction of outcome. Recent studies ...
... Bacillus Calmette-Guérin (BCG) treatment reduces recurrences and progression in patients with non-muscle-invasive bladder cancer (NMIBC).
... in models of pancreatic cancer invivo. The stress-regulated protein p8 is involved in THC-induced apoptosis of pancreatic tumor cells. Cannabinoids ...
PharmaCyte Biotech's treatment for pancreatic cancer involves low doses of the well-known anticancer prodrug ifosfamide, together with encapsulated ...
Researchers led by Alexandria Phan, MD, and Daniel Halperin, MD, of the MD AndersonCancer Center looked at 52 patients (32 with pancreatic ...
BMI1 has previously been implicated in pancreatic homeostasis and the function of pancreatic cancer stem cells. However, no work has yet addressed ...
in an ATP- and Ca 2+-dependent fashion ( Sainz et al., Cancer Cell,. 2013 ), which can be ... K-Ras-drivenpancreatic cancer via a Gata6 acinar.
Novel Biologic Agents for Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia—Part 2: Adoptive Cellular Immunotherapy, Small-Molecule Inhibitors, and Immunomodulation
Globally, the incidence of non-Hodgkin lymphoma is increasing. Aggressive non-Hodgkin lymphomas like diffuse large B-cell lymphoma are treated with curative intent in the frontline setting, but indolent diseases like chronic lymphocytic leukemia/small lymphocytic lymphoma are not considered to be curable in general. Additionally, relapsed/refractory non-Hodgkin lymphomas have a poor overall outcome, with treatment response durations often decreasing with each relapse. Novel therapies are sought to improve outcomes in this patient population. Here, in Part 2, we discuss adoptive cellular immunotherapies, small-molecule inhibitors, and immunomodulatory agents. We also mention other novel therapies on the horizon.
Globally, the incidence of non-Hodgkin lymphoma is increasing. Aggressive non-Hodgkin lymphomas like diffuse large B-cell lymphoma are treated with curative intent in the frontline setting, but indolent diseases like chronic lymphocytic leukemia/small lymphocytic lymphoma are not considered to be curable in general. Additionally, relapsed/refractory non-Hodgkin lymphomas have a poor overall outcome, with treatment response durations often decreasing with each relapse. Novel therapies are sought to improve outcomes in this patient population. Here, in Part 2, we discuss adoptive cellular immunotherapies, small-molecule inhibitors, and immunomodulatory agents. We also mention other novel therapies on the horizon.
Small Molecules, Big Challenges
With each passing year, chemotherapy is less and less a focus of interest. Instead, the focus is on the abundance of exciting new biologic and targeted agents that are bulldozing the therapeutic landscape in the lymphomas and chronic lymphocytic leukemia.
With each passing year, chemotherapy is less and less a focus of interest. Instead, the focus is on the abundance of exciting new biologic and targeted agents that are bulldozing the therapeutic landscape in the lymphomas and chronic lymphocytic leukemia.
Metformin May Not Improve Pancreatic Cancer Survival
Metformin, a common drug for type II diabetes, did not improve the survival of patients with pancreatic ductal adenocarcinoma.
Metformin, a common drug for type II diabetes, did not improve the survival of patients with pancreatic ductal adenocarcinoma.
Trabectedin Fails to Improve PFS in Soft-Tissue Sarcoma
Trabectedin failed to improve progression-free survival outcomes compared to doxorubicin as first-line therapy for advanced/metastatic soft-tissue sarcoma.
Trabectedin failed to improve progression-free survival outcomes compared to doxorubicin as first-line therapy for advanced/metastatic soft-tissue sarcoma.
International Experts Propose New Pediatric NHL Staging System
A revised International Pediatric Non-Hodgkin Lymphoma Staging System (IPNHLSS) could allow for more precise staging for children and adolescents with NHL.
A revised International Pediatric Non-Hodgkin Lymphoma Staging System (IPNHLSS) could allow for more precise staging for children and adolescents with NHL.
FDA Approves Ramucirumab for Second-Line Treatment of mCRC
The FDA has approved ramucirumab, a human VEGFR2 antagonist in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer.
The FDA has approved ramucirumab, a human VEGFR2 antagonist in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer.
Health Care Utilization High Among Older Adults With AML
Older adults with acute myeloid leukemia have a substantial health care burden and high rates of health care utilization even at the end of life.
Older adults with acute myeloid leukemia have a substantial health care burden and high rates of health care utilization even at the end of life.
Lenvatinib Offers Promising Response Rate in Thyroid Cancer
The multi-targeted TKI lenvatinib showed promise in a phase II trial of patients with advanced, radioiodine-refractory, differentiated thyroid cancer.
The multi-targeted TKI lenvatinib showed promise in a phase II trial of patients with advanced, radioiodine-refractory, differentiated thyroid cancer.
Science Daily Cancer News
Tomosynthesis detects 40% more breast cancers than traditional mammography does, according to a major screening study. This is the first large-scale study to compare the screening method with regular mammograms. The 3D X-ray technique is also more comfortable for women, as breast compression is halved.
The enzyme GMPS drives melanoma growth, researchers report. The scientists propose a new strategy for targeting that protein that may help advance toward a new melanoma treatment strategy.
Biological and medical scientists have been using flow cytometry to count cancer cells for the past 40 years. But the large instruments are expensive and can only be operated by trained personnel. By contrast the PoCyton cytometer is cheap to produce, no bigger than a shoebox, and automated, developers report.
Tambahkan Komentar